Skip to content

Scleroderma Clinical Trials Consortium

Advancing research for people with scleroderma

Welcome to the Scleroderma Clinical Trials Consortium (SCTC)

The Scleroderma Clinical Trials Consortium (SCTC) is a global network of researchers and healthcare professionals who have a particular interest and expertise in the care of, and research in, scleroderma (systemic sclerosis). Our mission is to enhance the development, execution, and analysis of clinical trials to improve treatment options and outcomes for patients with scleroderma worldwide.

At a glance

0
MEMBER
INSTITUTIONS
0
ACTIVE PARTICIPATING
COUNTRIES
0
INDUSTRY
PARTNERS

Upcoming Meeting

SCTC Working Groups

Our Working Groups are designed to focus discussion and establish collaborative research projects aimed at increasing the efficiency of clinical trials and observational studies or producing position papers representative of the opinions of a majority of our SCTC members.
Participate in our ongoing working groups

Learn about current research initiatives and find out how you can support and contribute to advancing scientific progress.

Our Mission

At SCTC, we are committed to:

Advancing standards of research for people with scleroderma by conducting, sponsoring, and facilitating projects that improve clinical outcomes with a special focus on clinical trials.

Why Scleroderma research matters

Scleroderma is a complex and rare autoimmune disease that affects the skin and internal organs, leading to severe complications, with limited treatment options. Through rigorous clinical research, we aim to uncover new therapies, refine treatment guidelines, and ultimately improve patient outcomes.

Our Work

Together, we can make a difference in the lives of those affected by scleroderma.

Get involved

You can contribute to scleroderma research in several ways: